Drug intelligence / Profile preview

ganciclovir + infliximab + mesalamine + rivaroxaban

Development stage: Unknown
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral, Rectal, Ophthalmic

Overview

This is a combination of four separate medications with different therapeutic purposes. Ganciclovir is an antiviral medication used to treat cytomegalovirus (CMV) infections. Infliximab is a monoclonal antibody that blocks tumor necrosis factor alpha (TNF-α), used for inflammatory conditions such as Crohn's disease and ulcerative colitis. Mesalamine is an anti-inflammatory drug used primarily for inflammatory bowel diseases. Rivaroxaban is an anticoagulant medication.

Targets

ALOX5 (Arachidonate 5-lipoxygenase)PGHS-1 (Prostaglandin G/H Synthase 1)TNFA (Tumor necrosis factor alpha (soluble))F10 (Factor Xa)CMV DNA polymerase (Human cytomegalovirus DNA polymerase)PPARG (Peroxisome proliferator-activated receptor gamma)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on ganciclovir + infliximab + mesalamine + rivaroxaban.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ganciclovir + infliximab + mesalamine + rivaroxaban.

Explore the full profile